In vitro studies with the platelet-reactive antibody 50H.19 and its fragments.
The platelet-reactive monoclonal antibody 50H.19, its F(ab')2 fragments, and 99m-technetium (99m-Tc)-labeled fragments used in thrombus imaging were evaluated for their ability to cause platelet aggregation. The intact antibody caused a dose-dependent platelet aggregation in either platelet-rich plasma (PRP) or defined buffer solutions. The F(ab')2 fragments did not cause platelet aggregation except at high calcium concentrations. Neither stannous-ion-treated antibody fragments nor 99m-Tc-labeled antibody fragments caused platelet aggregation. The antibody-induced platelet aggregation was completely inhibited by 8-bromo-cAMP, caffeine, theophylline diltiazem, and staurosporin; partially inhibited by EDTA, EGTA, cytochalasin B, colchicine, aspirin, or indomethacin. Treatment of platelets with the intact 50H.19 antibody resulted in phosphorylation of a 40K dalton platelet protein, similar to that caused by treatment with phorbol myristate acetate (PMA). Phosphorylization of the 40K protein was not observed after treatment with either the 50H.19 F(ab')2 fragments or the calcium ionophore A23187.
Shah
V O
VO
Summa Medical Corporation, Albuquerque, NM 87109.
Zamora
P O
PO
Mills
S L
SL
Mann
P L
PL
Comp
P C
PC
D000911:Antibodies, Monoclonal; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D066298:In Vitro Techniques; D008565:Membrane Proteins / Q000097:blood; D008970:Molecular Weight; D010766:Phosphorylation; D010974:Platelet Aggregation / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D008565:Membrane Proteins; D010975:Platelet Aggregation Inhibitors